
Alumis Inc (ALMS) Stock Forecast & Price Target
Alumis Inc (ALMS) Analyst Ratings
Bulls say
Alumis Inc demonstrates a strong potential for growth through its innovative pipeline, particularly highlighted by the promising efficacy and safety profile of A-005 in multiple sclerosis, which could translate to significant clinical advancements in targeted therapies. The company’s ongoing data improvements, especially with ESK-001 in psoriasis, suggest the possibility of outperforming existing market leaders such as OTEZLA, further enhancing its revenue prospects. Additionally, the confidence expressed by Acelyrin's board regarding the merger indicates a strategic alignment aimed at maximizing long-term value, reinforcing a positive outlook for shareholders of Alumis.
Bears say
Alumis Inc faces significant risks that could adversely impact its financial outlook, primarily centered on the advancement and efficacy of its lead product candidate, ESK-001. Key concerns include the potential inability to progress ESK-001 to pivotal trials timely, failure to demonstrate clinical efficacy, and delays in obtaining regulatory approvals in major markets, all of which could stifle revenue generation. Additionally, the company is subject to intense competition in the immunology and inflammation (I&I) therapeutic space, which could hinder market acceptance and lead to possible dilution risks for current shareholders.
This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.
Alumis Inc (ALMS) Analyst Forecast & Price Prediction
Start investing in Alumis Inc (ALMS)
Order type
Buy in
Order amount
Est. shares
0 shares